

FUNDING AND DISCLOSURE

Funding was provided by the National Institute of Mental Health (Grants R21MH109771 and K23MH094707 to J.W.M.) and the Doris Duke Charitable Foundation (Grant 2013098 to J.W.M.).

Additional funding for this study was provided by the Ehrenkranz Laboratory for Human Resilience, a component of the Depression and Anxiety Center for Discovery and Treatment at the Icahn School of Medicine at Mount Sinai. The content is solely the responsibility of the authors and does not necessarily represent the official views of the National Institutes of Health or other funding bodies.

In the past 5 years, J.W.M. has provided consultation services to Otsuka, Clexio Biosciences, FSV7, Boehringer Ingelheim, Sage Therapeutics, Novartis, Allergan, Fortress Biotech, Janssen Research and Development, Genentech, Medavante-Prophase, and Global Medical Education (GME) and has received research support from Avanir Pharmaceuticals, Inc. J.W.M. is named on a patent pending for neuropeptide Y as a treatment for mood and anxiety disorders.

D.C. is named as co-inventor on patents filed by the Icahn School of Medicine at Mount Sinai (ISMMS) relating to ketamine for the treatment for treatment-resistant depression, suicidal ideation, and other disorders. ISMMS has entered into a licensing agreement with Janssen Pharmaceuticals, Inc. and it has and will receive payments from Janssen under the license agreement related to these patents for the treatment of treatment-resistant depression and suicidal ideation. Consistent with the ISMMS Faculty Handbook (the medical school policy), D.C. is entitled to a portion of the payments received by the ISMMS. Since SPRAVATO has received regulatory approval for treatment-resistant depression, ISMMS and thus, through the ISMMS, D.C. will be entitled to additional payments, beyond those already received, under the license agreement. D.C. is a named co-inventor on several patents filed by ISMMS for a cognitive training intervention to treat depression and related psychiatric disorders. The ISMMS has entered into a licensing agreement with Click Therapeutics Inc. and has and will receive payments related to the use of this cognitive training intervention for the treatment of psychiatric disorders. In accordance with the ISMMS Faculty Handbook, D.C. has received a portion of these payments and is entitled to a portion of any additional payments that the medical school might receive from this license with Click Therapeutics. D.C. is a named co-inventor on a patent application filed by the ISMMS for the use of intranasally administered neuropeptide Y (NPY) for the treatment of mood and anxiety disorders. This intellectual property has not been licensed. D.C. is a named co-inventor on a patent application in the United States, and several issued patents outside the United States filed by the ISMMS related to the use of ketamine for the treatment of post-traumatic stress disorder (PTSD). This intellectual property has not been licensed

The authors declare no competing interests.